In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat
Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentActive18 and overNCINCI-2009-00587
CDR0000546714, GOG-0213, U10CA027469, NCT00565851

Trial Description

Summary

This randomized phase III trial is studying giving carboplatin, paclitaxel and gemcitabine together with or without bevacizumab after surgery to see how well it works in treating patients with recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether combination chemotherapy is more effective when given with or without bevacizumab after surgery in treating patients with recurrent ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer.

Further Study Information

PRIMARY OBJECTIVES:

I. To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases the duration of overall survival in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer.

II. To determine if the addition of bevacizumab to the second-line and maintenance phases of treatment increases the duration of overall survival relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer.

SECOND OBJECTIVES:

I. To determine if the addition of bevacizumab to the second-line and maintenance phase of treatment increases the duration of progression-free survival relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or Fallopian tube cancer.

II. To prospectively determine the incidence of carboplatin and paclitaxel hypersensitivity in these patients undergoing retreatment with both agents as first recurrence therapy.

III. To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases quality of life (QOL) of patients with recurrent platinum-sensitive ovarian epithelial cancer or primary peritoneal cavity cancer, as measured by the Functional Assessment of Cancer Therapy (FACT)-O trial outcome index and Rand SF-36 physical functioning scale.

IV. To determine if the addition of bevacizumab to the second-line and maintenance phases of treatment increases QOL relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum-sensitive ovarian epithelial cancer or primary peritoneal cavity cancer.

OUTLINE: This is a multicenter study. Patients are assigned to 1 of 4 treatment groups. Patients who are not candidates for surgical cytoreduction (i.e., those for whom complete cytoreduction in the estimation of the investigator is impossible or a medical infirmity precludes exploration and debulking) are eligible to receive chemotherapy after randomization.

Patients who are eligible for surgery undergo abdominal exploration with cytoreduction and undergo tumor tissue collection and complete a quality of life questionnaire before and after surgery. All patients are then randomized to 1 of 4 treatment arms.

ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours or docetaxel IV over 1 hour and carboplatin IV over 60 minutes on day 1.

ARM II: Patients receive chemotherapy as in arm I and bevacizumab IV over 30-90 minutes on day 1.

ARM III: Patients receive gemcitabine IV over 60 minutes on days 1and 8 and carboplatin as in arm I.

ARM IV: Patients receive gemcitabine IV as in arm III, bevacizumab IV and carboplatin IV as in arm II.

In all arms, treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.

Patients with measurable disease achieving a clinical response (CR) receive 6-8 courses of therapy. Patients with stable disease or partial regression receive a maximum of 6 courses.

Patients without measurable lesions as determined by a computed tomography (CT) scan prior to initiating study treatment continue therapy for 6 courses or, if CA-125 normalizes, for 2 cycles beyond CA-125 normalization, whichever is greater. Patients in arm II then receive a maintenance regimen comprising bevacizumab IV over 30-90 minutes. Treatment with bevacizumab alone repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically for 10 years.

Eligibility Criteria

Inclusion Criteria:

  • Patients must have histologic diagnosis of ovarian epithelial carcinoma, peritoneal primary or fallopian tube carcinoma, which is now recurrent
  • The following histologic epithelial cell types are eligible:
  • Serous adenocarcinoma
  • Endometrioid adenocarcinoma
  • Mucinous adenocarcinoma
  • Undifferentiated carcinoma
  • Clear cell adenocarcinoma
  • Mixed epithelial carcinoma
  • Transitional cell carcinoma
  • Malignant Brenner Tumor
  • Adenocarcinoma not otherwise specified
  • Patients must have had a complete response to front-line platinum-taxane therapy (at least 3 cycles) and a treatment-free interval without clinical evidence of progressive disease lasting at least 6 months
  • A complete response to front-line chemotherapy must include the following:
  • Negative physical exam
  • Negative pelvic exam
  • Normalization of CA125, if elevated at baseline
  • Negative radiographic assessment of disease
  • All patients must have also had a treatment-free interval without clinical evidence of progressive disease of at least 6 months from completion of front-line chemotherapy (both platinum and taxane); front-line therapy may have included a biologic agent
  • Front-line treatment may include maintenance therapy following complete clinical or pathological response; however, maintenance cytotoxic chemotherapy must be discontinued for a minimum of 6 months prior to documentation of recurrent disease; patients receiving maintenance biological therapy or hormonal therapy are ELIGIBLE provided their recurrence is documented more than 6 months from primary cytotoxic chemotherapy completion (includes maintenance chemotherapy) AND a minimum 4 weeks has elapsed since their last infusion of biological therapy
  • Patients must have clinically evident recurrent disease for the purpose of this study,
  • Measurable disease (RECIST) is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each lesion must be more than or equal to 20 mm when measured by conventional techniques, MRI or CT, or more than or equal to 10 mm when measured by spiral CT
  • Absolute neutrophil count (ANC) >= 1,500/mm^3 equivalent to Common Toxicity Criteria for Adverse Events v3.0 (CTCAE) Grade1
  • Platelet count >= 100,000/mm^3 (Common Terminology Criteria for Adverse Events [CTCAE] Grade 0-1)
  • Creatinine (non-isotope dilution mass spectrometry [IDMS]) =< 1.5 times upper limit of normal (ULN)
  • Total bilirubin =< 1.5 times ULN
  • Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) =< 2.5 times ULN (< 5.0 times ULN in the presence of liver metastasis)
  • Alkaline phosphatase =< 2.5 times ULN (< 5.0 times ULN in the presence of liver metastasis)
  • Patients must have a urine protein-to-creatinine ratio (UPCR) < 1.0 mg/dL
  • Patients who are not candidates for surgical cytoreduction are eligible for the chemotherapy randomization; patients are not considered candidates for surgical cytoreduction if complete cytoreduction in the estimation of the investigator is impossible or a medical infirmity precludes exploration and debulking
  • Patients must have signed an approved informed consent and authorization permitting release of personal health information
  • Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2

Exclusion Criteria:

  • Patients who have more than one previous regimen of chemotherapy (maintenance therapy is not considered a second regimen)
  • Patients receiving concurrent immunotherapy, or radiotherapy
  • Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded
  • Patients whom have already undergone secondary cytoreduction for recurrent disease are excluded
  • Patients with a prior histologic diagnosis of borderline, low malignant potential (grade 0) epithelial carcinoma that was surgically resected and who subsequently developed an unrelated, new invasive epithelial ovarian or peritoneal primary cancer are eligible provided they meet the inclusion criteria above
  • Patients who require parenteral hydration or nutrition and have evidence of partial bowel obstruction or perforation
  • Patients with synchronous primary endometrial cancer, or a past history of primary endometrial cancer are excluded, unless all of the following conditions are met:
  • Stage not greater than I-B;
  • No more than superficial myometrial invasion, without vascular or lymphatic invasion;
  • No poorly differentiated subtypes, including papillary serous, clear cell or other International Federation of Gynecology and Obstetrics (FIGO) Grade 3 lesions
  • Patients with uncontrolled infection
  • Patients with concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or expose the patient to extreme risk or decreased life expectancy
  • Patients with peripheral neuropathy >= grade 2
  • Patients with a history of allergic reactions to carboplatin and/or paclitaxel or chemically similar compounds; patients with allergic (hypersensitivity) reactions to these chemotherapeutic agents are NOT excluded IF they were successfully retreated following a desensitization program or protocol
  • Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
  • Patients of childbearing potential, not practicing adequate contraception, patients who are pregnant or patients who are nursing are not eligible for this trial; to date, no fetal studies in animal or humans have been performed; the possibility of harm to a fetus is likely; bevacizumab specifically inhibits VEGF, which is responsible for the formation of new blood vessels during development, and antibodies can cross the placenta; therefore, bevacizumab should not be administered to pregnant women; in addition, there are unknown immediate and long-term consequences of chemotherapy administration to these women; in addition, surgical exploration as mandated by randomization during pregnancy may cause imminent mortal consequences; further, it is not known whether bevacizumab is excreted in human milk; because many drugs are excreted in human milk, bevacizumab should not be administered to nursing women; subjects will be apprised of the large potential risk to a developing fetus
  • Patients with other invasive malignancies, with the exception of nonmelanoma skin cancer, or patients who had (or have) any evidence of the other cancer present within the past 5 years or whose previous cancer treatment contraindicates this protocol therapy
  • Patients with active bleeding or pathologic conditions that carry high risk of bleeding such as a known bleeding disorder, coagulopathy, or tumor involving major vessels
  • Patients with a history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or a history of stroke within the past 5 years of the first date of treatment on this study
  • Patients with clinically significant cardiovascular disease including any of the following:
  • Significant cardiac conduction abnormalities (e.g., PR interval > 0.24 sec or 2nd or 3rd degree atrioventricular [AV] block )
  • Uncontrolled hypertension, defined as systolic blood pressure (BP) > 150 mm Hg or diastolic BP > 90 mm Hg
  • Myocardial infarction, cardiac arrhythmia, or unstable angina within the past 6 months
  • New York Heart Association (NYHA) grade II or greater congestive heart failure
  • Serious cardiac arrhythmia requiring medication
  • Grade II or greater peripheral vascular disease except episodes of ischemia < 24 hrs in duration that are managed non-surgically and without permanent deficit
  • History of cerebrovascular accident (CVA) within the past 6 months
  • Patients who have had a major surgical procedure, open biopsy, dental extractions or other dental surgery/procedure that results in an open wound, or significant traumatic injury within 28 days prior to the first date of treatment on this study, or anticipation of need for major surgical procedure during the course of the study; patients with placement of vascular access device or core biopsy within 7 days prior to the first date of treatment on this study:
  • Patients undergoing pre-treatment secondary cytoreduction will undergo therapy with bevacizumab on cycle 2
  • Patients undergoing pre-treatment surgery for purposes other than cytoreduction may also participate provided they meet eligibility; patients randomized to arms containing bevacizumab must wait a minimum of 28 days since that procedure to begin protocol treatment; patients who undergo an uncomplicated port placement must wait a minimum of 7 days to begin protocol treatment

Trial Contact Information

Trial Lead Organizations/Sponsors

National Cancer Institute

Robert L. ColemanPrincipal Investigator

Trial Sites

U.S.A.
Alaska
  Anchorage
 Alaska Breast Care and Surgery LLC
 Alison K Conlin Ph: 503-215-6412
 Katmai Oncology Group
 Alison K Conlin Ph: 503-215-6412
 Providence Cancer Center
 Alison K Conlin Ph: 503-215-6412
Arizona
  Phoenix
 GOG of Arizona, PC
 Robert L. Coleman Ph: 713-792-3245
  Email: rcoleman@mdanderson.org
California
  Concord
 Cancer Care Center at John Muir Health - Concord Campus
 Babak Edraki Ph: 925-674-2580
  Long Beach
 Todd Cancer Institute at Long Beach Memorial Medical Center
 Robert E Bristow Ph: 562-933-0900
  Email: ucstudy@uci.edu
  Los Angeles
 Jonsson Comprehensive Cancer Center at UCLA
 Robin Farias-Eisner Ph: 888-798-0719
 Kaiser Permanente Medical Center - Los Angeles
 Scott E. Lentz Ph: 626-564-3455
 Scott E. Lentz Ph: 626-564-3455
  Mountain View
 Palo Alto Medical Foundation
 Albert L Pisani Ph: 650-934-7000
  Orange
 Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
 Krishnansu S Tewari Ph: 714-456-6191
  Email: awallick@uci.edu
  San Francisco
 UCSF Helen Diller Family Comprehensive Cancer Center
 Lee-may Chen Ph: 877-827-3222
  Stanford
 Stanford Cancer Center
 Jonathan S. Berek Ph: 650-498-7061
  Email: clinicaltrials@med.stanford.edu
  Walnut Creek
 John Muir/Mt. Diablo Comprehensive Cancer Center
 Babak Edraki Ph: 925-674-2580
Colorado
  Aurora
 Medical Center of Aurora - South Campus
 Keren Sturtz Ph: 888-785-6789
 University of Colorado Cancer Center at UC Health Sciences Center
 Susan Davidson Ph: 720-848-0650
  Boulder
 Boulder Community Hospital
 Keren Sturtz Ph: 888-785-6789
  Colorado Springs
 Penrose Cancer Center at Penrose Hospital
 Keren Sturtz Ph: 888-785-6789
  Denver
 CCOP - Colorado Cancer Research Program
 Keren Sturtz Ph: 888-785-6789
 Porter Adventist Hospital
 Keren Sturtz Ph: 888-785-6789
 Presbyterian - St. Luke's Medical Center
 Keren Sturtz Ph: 888-785-6789
 Rose Medical Center
 Keren Sturtz Ph: 888-785-6789
 St. Joseph Hospital
 Keren Sturtz Ph: 888-785-6789
  Durango
 Mercy Medical Center
 Cynthia K. Cathcart Ph: 888-785-6789
  Englewood
 Swedish Medical Center
 Keren Sturtz Ph: 888-785-6789
  Greeley
 North Colorado Medical Center
 Keren Sturtz Ph: 888-785-6789
  Lakewood
 St. Anthony Central Hospital
 Keren Sturtz Ph: 888-785-6789
  Littleton
 Littleton Adventist Hospital
 Keren Sturtz Ph: 888-785-6789
  Lone Tree
 Sky Ridge Medical Center
 Keren Sturtz Ph: 888-785-6789
  Longmont
 Hope Cancer Care Center at Longmont United Hospital
 Keren Sturtz Ph: 888-785-6789
  Loveland
 McKee Medical Center
 Keren Sturtz Ph: 888-785-6789
  Parker
 Parker Adventist Hospital
 Keren Sturtz Ph: 888-785-6789
  Pueblo
 St. Mary - Corwin Regional Medical Center
 Keren Sturtz Ph: 888-785-6789
  Wheat Ridge
 Exempla Lutheran Medical Center
 Keren Sturtz Ph: 888-785-6789
Connecticut
  Farmington
 Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
 Angela S Kueck Ph: 800-579-7822
  Hartford
 Helen and Harry Gray Cancer Center at Hartford Hospital
 James S. Hoffman Ph: 860-224-5660
 Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
 Philip J. Stella Ph: 734-712-3456
  Middletown
 Middlesex Hospital Cancer Center
 Jonathan Cosin Ph: 860-224-5660
  New Britain
 George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
 James S. Hoffman Ph: 860-224-5660
Delaware
  Lewes
 Tunnell Cancer Center at Beebe Medical Center
 Mark E Borowsky Ph: 302-733-6227
  Newark
 Helen F. Graham Cancer Center at Christiana Hospital
 Mark E Borowsky Ph: 302-733-6227
Georgia
  Columbus
 John B. Amos Cancer Center
 John L Currie Ph: 860-545-5363
  Gainesville
 Northeast Georgia Medical Center
 Andrew E Green Ph: 770-219-8800
  Email: cancerpatient.navigator@nghs.com
  Savannah
 Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler
 William Edward Richards Ph: 800-622-6877
  Email: uchealthnews@uc.edu
Idaho
  Boise
 Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
 Philip J. Stella Ph: 734-712-3456
Illinois
  Aurora
 Rush-Copley Cancer Care Center
 Kendrith M. Rowland Ph: 800-446-5532
  Chicago
 Robert H. Lurie Comprehensive Cancer Center at Northwestern University
 Julian C. Schink Ph: 616-391-3050
  Email: cancer@northwestern.edu
 University of Chicago Cancer Research Center
 Seiko Diane Yamada Ph: 773-834-7424
  Hinsdale
 Gynecologic Oncology
 Sudarshan K. Sharma Ph: 630-856-6757
  Mount Vernon
 Good Samaritan Regional Health Center
 Jay W Carlson Ph: 888-244-6061
  Email: sherrijr@iora.org
  Urbana
 Carle Cancer Center at Carle Foundation Hospital
 Kendrith M. Rowland Ph: 800-446-5532
Indiana
  Elkhart
 Elkhart Clinic, LLC
 Michael Rodriguez Ph: 574-237-1328
 Elkhart General Hospital
 Michael Rodriguez Ph: 574-237-1328
 Michiana Hematology-Oncology, PC - Elkhart
 Michael Rodriguez Ph: 574-237-1328
  Indianapolis
 Indiana University Melvin and Bren Simon Cancer Center
 Jeanne M Schilder Ph: 317-274-2552
 St. Vincent Oncology Center
 Gregory P. Sutton Ph: 317-338-2194
  Kokomo
 Community Cancer Care at Howard Regional Health System
 Michael Rodriguez Ph: 574-237-1328
  La Porte
 Center for Cancer Therapy at LaPorte Hospital and Health Services
 Michael Rodriguez Ph: 574-237-1328
  Michigan City
 Saint Anthony Memorial Health Centers
 Kendrith M. Rowland Ph: 800-446-5532
  Mishawaka
 Michiana Hematology-Oncology, PC - Mishawaka
 Michael Rodriguez Ph: 574-237-1328
 Saint Joseph's Medical Center
 Michael Rodriguez Ph: 574-237-1328
  Munster
 Community Hospital
 Mohamad Kassar Ph: 219-836-3349
  Plymouth
 Michiana Hematology Oncology PC - Plymouth
 Michael Rodriguez Ph: 574-237-1328
  South Bend
 CCOP - Northern Indiana CR Consortium
 Michael Rodriguez Ph: 574-237-1328
 Michiana Hematology-Oncology, PC - South Bend
 Michael Rodriguez Ph: 574-237-1328
 South Bend Clinic
 Michael Rodriguez Ph: 574-237-1328
  Westville
 Michiana Hematology Oncology-PC Westville
 Michael Rodriguez Ph: 574-237-1328
Iowa
  Clive
 Medical Oncology and Hematology Associates-West Des Moines
 Robert J Behrens Ph: 888-244-6061
  Email: sherrijr@iora.org
 Mercy Cancer Center - West Lakes
 Robert J Behrens Ph: 888-244-6061
  Email: sherrijr@iora.org
  Des Moines
 CCOP - Iowa Oncology Research Association
 Robert J Behrens Ph: 888-244-6061
  Email: sherrijr@iora.org
 John Stoddard Cancer Center at Iowa Lutheran Hospital
 Robert J Behrens Ph: 888-244-6061
  Email: sherrijr@iora.org
 John Stoddard Cancer Center at Iowa Methodist Medical Center
 Robert J Behrens Ph: 888-244-6061
  Email: sherrijr@iora.org
 Medical Oncology and Hematology Associates at John Stoddard Cancer Center
 Robert J Behrens Ph: 888-244-6061
  Email: sherrijr@iora.org
 Medical Oncology and Hematology Associates at Mercy Cancer Center
 Robert J Behrens Ph: 888-244-6061
  Email: sherrijr@iora.org
 Mercy Cancer Center at Mercy Medical Center - Des Moines
 Robert J Behrens Ph: 888-244-6061
  Email: sherrijr@iora.org
  Iowa City
 Holden Comprehensive Cancer Center at University of Iowa
 David P Bender Ph: 800-237-1225
  West Des Moines
 Methodist West Hospital
 Robert J Behrens Ph: 888-244-6061
  Email: sherrijr@iora.org
 Robert J Behrens Ph: 888-244-6061
  Email: sherrijr@iora.org
Kansas
  Chanute
 Cancer Center of Kansas, PA - Chanute
 Shaker R. Dakhil Ph: 316-262-4467
  Dodge City
 Cancer Center of Kansas, PA - Dodge City
 Shaker R. Dakhil Ph: 316-262-4467
  El Dorado
 Cancer Center of Kansas, PA - El Dorado
 Shaker R. Dakhil Ph: 316-262-4467
  Fort Scott
 Cancer Center of Kansas - Fort Scott
 Shaker R. Dakhil Ph: 316-262-4467
  Independence
 Cancer Center of Kansas-Independence
 Shaker R. Dakhil Ph: 316-262-4467
  Kingman
 Cancer Center of Kansas, PA - Kingman
 Shaker R. Dakhil Ph: 316-262-4467
  Lawrence
 Lawrence Memorial Hospital
 Shaker R. Dakhil Ph: 316-262-4467
  Liberal
 Cancer Center of Kansas, PA - Liberal
 Shaker R. Dakhil Ph: 316-262-4467
  Manhattan
 Cancer Center of Kansas-Manhattan
 Shaker R. Dakhil Ph: 316-262-4467
  McPherson
 Cancer Center of Kansas, PA - McPherson
 Shaker R. Dakhil Ph: 316-262-4467
  Newton
 Cancer Center of Kansas, PA - Newton
 Shaker R. Dakhil Ph: 316-262-4467
  Parsons
 Cancer Center of Kansas, PA - Parsons
 Shaker R. Dakhil Ph: 316-262-4467
  Pratt
 Cancer Center of Kansas, PA - Pratt
 Shaker R. Dakhil Ph: 316-262-4467
  Salina
 Cancer Center of Kansas, PA - Salina
 Shaker R. Dakhil Ph: 316-262-4467
  Wellington
 Cancer Center of Kansas, PA - Wellington
 Shaker R. Dakhil Ph: 316-262-4467
  Wichita
 Associates in Women's Health, PA - North Hillside
 Shaker R. Dakhil Ph: 316-262-4467
 Cancer Center of Kansas, PA - Medical Arts Tower
 Shaker R. Dakhil Ph: 316-262-4467
 Cancer Center of Kansas, PA - Wichita
 Shaker R. Dakhil Ph: 316-262-4467
 CCOP - Wichita
 Shaker R. Dakhil Ph: 316-262-4467
 Via Christi Cancer Center at Via Christi Regional Medical Center
 Shaker R. Dakhil Ph: 316-262-4467
 Wesley Medical Center
 Shaker R. Dakhil Ph: 316-262-4467
  Winfield
 Cancer Center of Kansas, PA - Winfield
 Shaker R. Dakhil Ph: 316-262-4467
Kentucky
  Louisville
 University of Louisville School of Medicine
 Lynn P Parker Ph: 866-530-5516
Louisiana
  Baton Rouge
 Hematology-Oncology Clinic
 William R. Robinson Ph: 504-988-6121
  New Orleans
 Tulane Cancer Center at Tulane University Hospital and Clinic
 William R. Robinson Ph: 504-988-6121
Maryland
  Baltimore
 Greater Baltimore Medical Center Cancer Center
 Amanda N Fader Ph: 410-955-8804
  Email: jhcccro@jhmi.edu
Massachusetts
  Worcester
 Levine Cancer Center at UMass Medical Center - Memorial Campus
 Susan L. Zweizig Ph: 508-856-3216
  Email: cancer.research@umassmed.edu
Michigan
  Ann Arbor
 CCOP - Michigan Cancer Research Consortium
 Philip J. Stella Ph: 734-712-3456
 Saint Joseph Mercy Cancer Center
 Philip J. Stella Ph: 734-712-3456
 University of Michigan Comprehensive Cancer Center
 Carolyn M. Johnston Ph: 734-712-3456
  Battle Creek
 Battle Creek Health System Cancer Care Center
 Gilbert D Padula Ph: 616-685-5225
  Big Rapids
 Mecosta County Medical Center
 Gilbert D Padula Ph: 616-685-5225
  Dearborn
 Oakwood Cancer Center at Oakwood Hospital and Medical Center
 Philip J. Stella Ph: 734-712-3456
  Detroit
 Josephine Ford Cancer Center at Henry Ford Hospital
 Thomas E Buekers Ph: 313-916-1784
 Van Elslander Cancer Center at St. John Hospital and Medical Center
 Philip J. Stella Ph: 734-712-3456
 Wayne State University
 Robert T. Morris Ph: 313-576-9363
  Escanaba
 Green Bay Oncology, Limited - Escanaba
 Jonathan E Tammela Ph: 920-433-8889
  Flint
 Genesys Hurley Cancer Institute
 Philip J. Stella Ph: 734-712-3456
 Hurley Medical Center
 Philip J. Stella Ph: 734-712-3456
  Grand Rapids
 Butterworth Hospital at Spectrum Health
 Gilbert D Padula Ph: 616-685-5225
 CCOP - Grand Rapids
 Gilbert D Padula Ph: 616-685-5225
 Lacks Cancer Center at Saint Mary's Health Care
 Gilbert D Padula Ph: 616-685-5225
  Iron Mountain
 Green Bay Oncology - Iron Mountain
 Jonathan E Tammela Ph: 920-433-8889
  Jackson
 Gayle M. Jacob Cancer Center at Allegiance Health
 Philip J. Stella Ph: 734-712-3456
  Kalamazoo
 Borgess Medical Center
 Raymond Sterling Lord Ph: 269-373-7458
 Bronson Methodist Hospital
 Raymond Sterling Lord Ph: 269-373-7458
 West Michigan Cancer Center
 Raymond Sterling Lord Ph: 269-373-7458
  Lansing
 Sparrow Regional Cancer Center
 Philip J. Stella Ph: 734-712-3456
  Livonia
 St. Mary Mercy Hospital
 Philip J. Stella Ph: 734-712-3456
  Muskegon
 Mercy General Health Partners
 Gilbert D Padula Ph: 616-685-5225
  Pontiac
 St. Joseph Mercy Oakland
 Philip J. Stella Ph: 734-712-3456
  Port Huron
 Mercy Regional Cancer Center at Mercy Hospital
 Philip J. Stella Ph: 734-712-3456
  Reed City
 Spectrum Health Reed City Hospital
 Gilbert D Padula Ph: 616-685-5225
  Saginaw
 Seton Cancer Institute at Saint Mary's - Saginaw
 Philip J. Stella Ph: 734-712-3456
  Saint Joseph
 Lakeside Cancer Specialists, PLLC
 Michael Rodriguez Ph: 574-237-1328
  St. Joseph
 Lakeland Regional Cancer Care Center - St. Joseph
 Michael Rodriguez Ph: 574-237-1328
  Traverse City
 Munson Medical Center
 Gilbert D Padula Ph: 616-685-5225
  Warren
 St. John Macomb Hospital
 Philip J. Stella Ph: 734-712-3456
Minnesota
  Bemidji
 MeritCare Bemidji
 Maria C. Bell Ph: 218-333-5000
  Burnsville
 Fairview Ridges Hospital
 Patrick J. Flynn Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Coon Rapids
 Mercy and Unity Cancer Center at Mercy Hospital
 Patrick J. Flynn Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Duluth
 St. Luke's Hospital Cancer Care Center
 Basem S Goueli
  Email: sgriffin@gog.org
  Edina
 Fairview Southdale Hospital
 Patrick J. Flynn Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Fridley
 Mercy and Unity Cancer Center at Unity Hospital
 Patrick J. Flynn Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Hutchinson
 Hutchinson Area Health Care
 Patrick J. Flynn Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Maplewood
 HealthEast Cancer Care at St. John's Hospital
 Matthew P Boente Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
 Minnesota Oncology - Maplewood
 Matthew P Boente Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Minneapolis
 Hennepin County Medical Center - Minneapolis
 Matthew P Boente Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
 Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
 Matthew P Boente Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  New Ulm
 New Ulm Medical Center
 Patrick J. Flynn Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Robbinsdale
 Humphrey Cancer Center at North Memorial Outpatient Center
 Matthew P Boente Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Saint Louis Park
 CCOP - Metro-Minnesota
 Matthew P Boente Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
 Park Nicollet Cancer Center
 Matthew P Boente Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Saint Paul
 Regions Hospital Cancer Care Center
 Matthew P Boente Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
 United Hospital
 Patrick J. Flynn Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Shakopee
 St. Francis Cancer Center at St. Francis Medical Center
 Patrick J. Flynn Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Stillwater
 Lakeview Hospital
 Matthew P Boente Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Waconia
 Ridgeview Medical Center
 Matthew P Boente Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Willmar
 Willmar Cancer Center at Rice Memorial Hospital
 Matthew P Boente Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Woodbury
 Minnesota Oncology - Woodbury
 Matthew P Boente Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
Mississippi
  Jackson
 St. Dominic Cancer Center
 Donald P Seago Ph: 601-200-3300
 University of Mississippi Cancer Clinic
 James Tate Thigpen Ph: 601-815-6700
  Pascagoula
 Regional Cancer Center at Singing River Hospital
 James E. Clarkson Ph: 228-809-5292
Missouri
  Bolivar
 Central Care Cancer Center at Carrie J. Babb Cancer Center
 Jay W Carlson Ph: 888-244-6061
  Email: sherrijr@iora.org
  Branson
 Skaggs Cancer Center at Skaggs Regional Medical Center
 Jay W Carlson Ph: 888-244-6061
  Email: sherrijr@iora.org
  Columbia
 Ellis Fischel Cancer Center at University of Missouri - Columbia
 Mark I Hunter Ph: 573-882-7440
  Joplin
 Freeman Cancer Institute at Freeman Health System
 Jay W Carlson Ph: 888-244-6061
  Email: sherrijr@iora.org
 St. John's Regional Medical Center
 Jay W Carlson Ph: 888-244-6061
  Email: sherrijr@iora.org
  Rolla
 Mercy Clinic Cancer and Hematology - Rolla
 Jay W Carlson Ph: 888-244-6061
  Email: sherrijr@iora.org
 Phelps County Regional Medical Center
 Jay W Carlson Ph: 888-244-6061
  Email: sherrijr@iora.org
  Saint Louis
 David C. Pratt Cancer Center at St. John's Mercy
 Jay W Carlson Ph: 888-244-6061
  Email: sherrijr@iora.org
 Mercy Clinic St. Louis Cancer and Breast Institute
 Jay W Carlson Ph: 888-244-6061
  Email: sherrijr@iora.org
 Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
 David Gardner Mutch Ph: 800-600-3606
  Email: info@ccadmin.wustl.edu
  Springfield
 Hulston Cancer Center at Cox Medical Center South
 Jay W Carlson Ph: 888-244-6061
  Email: sherrijr@iora.org
 St. John's Regional Health Center
 Jay W Carlson Ph: 888-244-6061
  Email: sherrijr@iora.org
Nebraska
  Omaha
 Methodist Estabrook Cancer Center
 Peter C. Morris Ph: 402-354-7939
  Email: kathryn.bartz@nmhs.org
Nevada
  Las Vegas
 Women's Cancer Center - La Canada
 Nick M. Spirtos Ph: 702-851-4672
  Reno
 Renown Institute for Cancer at Renown Regional Medical Center
 Peter C Lim Ph: 866-513-8227
 Peter C Lim Ph: 866-513-8227
New Jersey
  Camden
 Cancer Institute of New Jersey at Cooper University Hospital - Camden
 David P. Warshal Ph: 856-325-6757
  Morristown
 Carol G. Simon Cancer Center at Morristown Memorial Hospital
 Daniel H Tobias Ph: 973-971-5900
  Mount Holly
 Virtua Fox Chase Health Cancer Program at Virtua Memorial Hospital Burlington County
 Randolph B Deger Ph: 888-847-8823
  Neptune
 Jersey Shore Cancer Center at Jersey Shore University Medical Center
 Michael R Manuel Ph: 732-776-4240
  Email: clinicaltrials@med.stanford.edu
  Phillipsburg
 Women’s Institute for Gynecologic Cancer and Special Pelvic Surgery
 David Foster Silver Ph: 718-765-2500
  Voorhees
 Fox Chase Virtua Health Cancer Program at Virtua West Jersey
 Randolph B Deger Ph: 888-847-8823
New Mexico
  Albuquerque
 Southwest Gynecologic Oncology Associates, Incorporated
 Carolyn Y. Muller Ph: 505-272-6972
 University of New Mexico Cancer Center
 Carolyn Y. Muller Ph: 505-272-6972
  Las Cruces
 Memorial Medical Center
 Carolyn Y. Muller Ph: 505-272-6972
New York
  Albany
 Women's Cancer Care Associates
 Thomas P Morrissey Ph: 518-458-1390
  Brightwaters
 Schwartz Oncology
 Benjamin M Schwartz Ph: 631-376-0055ext107
  Brooklyn
 SUNY Downstate Medical Center
 Ovadia Abulafia Ph: 718-270-8216
  Email: sima.terebelo@downstate.edu
  Lake Success
 Monter Cancer Center of the North Shore-LIJ Health System
 Veena S John Ph: 516-562-3467
  Manhasset
 Don Monti Comprehensive Cancer Center at North Shore University Hospital
 Veena S John Ph: 516-562-3467
  New Hyde Park
 Long Island Jewish Medical Center
 Veena S John Ph: 516-562-3467
  New York
 Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
 Thomas J. Herzog Ph: 212-305-8615
 Memorial Sloan-Kettering Cancer Center
 Mario M Leitao Ph: 212-639-7202
 Mount Sinai Medical Center
 Jamal Rahaman Ph: 212-824-7320
  Email: jenny.figueroa@mssm.edu
 New York University Medical Center
 Stephanie V. Blank Ph: 212-263-4434
  Email: prmc.coordinator@nyumc.org
  Stony Brook
 Stony Brook University Cancer Center
 Michael L. Pearl Ph: 800-862-2215
  Syracuse
 SUNY Upstate Medical University Hospital
 Mary J Cunningham Ph: 315-464-5476
North Carolina
  Asheboro
 Randolph Hospital
 Peter Rubin Ph: 336-832-0821
  Burlington
 Alamance Cancer Center at Alamance Regional Medical Center
 Janak K. Choksi Ph: 336-538-7725
  Charlotte
 Blumenthal Cancer Center at Carolinas Medical Center
 Robert Victor Higgins Ph: 704-355-2884
  Durham
 Duke Cancer Institute
 Angeles Alvarez Secord Ph: 888-275-3853
  Greensboro
 Moses Cone Regional Cancer Center at Wesley Long Community Hospital
 Peter Rubin Ph: 336-832-0821
  Raleigh
 Duke Health Raleigh Hospital
 Angeles Alvarez Secord Ph: 888-275-3853
  Reidsville
 Annie Penn Cancer Center
 Peter Rubin Ph: 336-832-0821
  Winston-Salem
 Wake Forest University Comprehensive Cancer Center
 Samuel S. Lentz Ph: 336-713-6771
North Dakota
  Bismarck
 Medcenter One Hospital Cancer Care Center
 Maria C. Bell Ph: 218-333-5000
  Fargo
 Roger Maris Cancer Center at MeritCare Hospital
 Maria C. Bell Ph: 218-333-5000
 Maria C. Bell Ph: 218-333-5000
 Sanford Clinic North-Fargo
 Maria C. Bell Ph: 218-333-5000
Ohio
  Akron
 Summa Center for Cancer Care at Akron City Hospital
 Vivian von Gruenigen Ph: 330-375-6101
  Canton
 Aultman Cancer Center at Aultman Hospital
 Michael P. Hopkins Ph: 330-363-6891
  Cincinnati
 University of Cincinnati
 Thomas J. Reid Ph: 937-298-3399
  Email: uchealthnews@uc.edu
  Cleveland
 Case Comprehensive Cancer Center
 Steven E. Waggoner Ph: 800-641-2422
 Cleveland Clinic Cancer Center at Fairview Hospital
 Peter Graham Rose Ph: 866-223-8100
 Cleveland Clinic Taussig Cancer Center
 Peter Graham Rose Ph: 866-223-8100
 MetroHealth Cancer Care Center at MetroHealth Medical Center
 Peter Graham Rose Ph: 866-223-8100
  Columbus
 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
 David M O'Malley Ph: 866-627-7616
  Email: osu@emergingmed.com
 Riverside Methodist Hospital Cancer Care
 Jeffrey G. Bell Ph: 614-566-4475
  Kettering
 Charles F. Kettering Memorial Hospital
 Thomas J. Reid Ph: 937-298-3399
  Email: uchealthnews@uc.edu
  Mayfield Heights
 Hillcrest Cancer Center at Hillcrest Hospital
 Peter Graham Rose Ph: 866-223-8100
  Mentor
 Lake/University Ireland Cancer Center
 Steven E. Waggoner Ph: 800-641-2422
Oklahoma
  Oklahoma City
 Oklahoma University Cancer Institute
 Robert S. Mannel Ph: 405-271-4272
  Email: julie-traylor@ouhsc.edu
  Tulsa
 Cancer Care Associates-Yale
 Robert S. Mannel Ph: 405-271-4272
  Email: julie-traylor@ouhsc.edu
 Natalie Warren Bryant Cancer Center at St. Francis Hospital
 David G. McIntosh Ph: 601-815-6700
Oregon
  Clackamas
 Clackamas Radiation Oncology Center
 Alison K Conlin Ph: 503-215-6412
  Milwaukie
 Providence Milwaukie Hospital
 Alison K Conlin Ph: 503-215-6412
  Newberg
 Providence Newberg Medical Center
 Alison K Conlin Ph: 503-215-6412
  Oregon City
 Willamette Falls Hospital
 Alison K Conlin Ph: 503-215-6412
  Portland
 CCOP - Columbia River Oncology Program
 Alison K Conlin Ph: 503-215-6412
 Knight Cancer Institute at Oregon Health and Science University
 Tanja Pejovic Ph: 503-494-1080
  Email: trials@ohsu.edu
 Providence Cancer Center at Providence Portland Medical Center
 Alison K Conlin Ph: 503-215-6412
 Providence St. Vincent Medical Center
 Alison K Conlin Ph: 503-215-6412
Pennsylvania
  Abington
 Rosenfeld Cancer Center at Abington Memorial Hospital
 Parviz Hanjani Ph: 215-481-2402
  Allentown
 Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
 M Bijoy Thomas Ph: 610-402-2273
  Bethlehem
 Lehigh Valley Hospital - Muhlenberg
 M Bijoy Thomas Ph: 610-402-2273
  Danville
 Geisinger Cancer Institute at Geisinger Health
 James R Bosscher Ph: 570-271-5251
  Email: ehicks@sprg.mercy.net
  Hazleton
 Geisinger Hazleton Cancer Center
 James R Bosscher Ph: 570-271-5251
  Email: ehicks@sprg.mercy.net
  Hershey
 Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center
 James Fanning Ph: 717-531-3779
  Email: CTO@hmc.psu.edu
  Philadelphia
 Abramson Cancer Center of the University of Pennsylvania
 Stephen C. Rubin Ph: 215-728-4790
 Fox Chase Cancer Center - Philadelphia
 Robert A. Burger Ph: 215-746-7406
 Gynecologic Oncology Group
 Robert L. Coleman Ph: 713-745-3357
  Email: rcoleman@mdanderson.org
 Temple Cancer Center at Temple University Hospital
 Enrique Hernandez Ph: 215-728-2983
  State College
 Geisinger Medical Group - Scenery Park
 James R Bosscher Ph: 570-271-5251
  Email: ehicks@sprg.mercy.net
  West Reading
 McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
 Bernice L Robinson-Bennett Ph: 610-988-9323
  Wilkes-Barre
 Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
 James R Bosscher Ph: 570-271-5251
  Email: ehicks@sprg.mercy.net
Rhode Island
  Providence
 Women and Infants Hospital of Rhode Island
 Paul A. DiSilvestro Ph: 401-274-1122
South Carolina
  Charleston
 Hollings Cancer Center at Medical University of South Carolina
 Whitney S Graybill Ph: 843-792-9321
South Dakota
  Rapid City
 Black Hills Obstetrics & Gynecology LLP
 Helen L. Frederickson Ph: 605-343-9224
  Sioux Falls
 Avera Cancer Institute
 Luis A Rojas-Espaillat Ph: 800-657-4377
  Email: Jan.Healy@avera.org
 Sanford Cancer Center at Sanford USD Medical Center
 Maria C. Bell Ph: 218-333-5000
 Maria C. Bell Ph: 218-333-5000
Texas
  Austin
 University Medical Center Brackenridge
 Mark A Crozier Ph: 512-324-7991
  Dallas
 Parkland Memorial Hospital
 David Scott Miller Ph: 214-648-7097
 Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
 David Scott Miller Ph: 214-648-7097
  Galveston
 University of Texas Medical Branch
 Lyuba Levine Ph: 409-772-1950
  Email: clinical.research@utmb.edu
  Houston
 Methodist Hospital
 Aparna A Kamat Ph: 713-790-2700
Utah
  Ogden
 Val and Ann Browning Cancer Center at McKay-Dee Hospital Center
 Ross E. Morgan Ph: 801-581-4477
  Email: clinical.trials@hci.utah.edu
  Provo
 Utah Valley Regional Medical Center - Provo
 Ross E. Morgan Ph: 801-581-4477
  Email: clinical.trials@hci.utah.edu
  Saint George
 Dixie Regional Medical Center - East Campus
 Ross E. Morgan Ph: 801-581-4477
  Email: clinical.trials@hci.utah.edu
  Salt Lake City
 Huntsman Cancer Institute at University of Utah
 Theresa L Werner Ph: 801-581-4477
  Email: clinical.trials@hci.utah.edu
 LDS Hospital
 Ross E. Morgan Ph: 801-581-4477
  Email: clinical.trials@hci.utah.edu
Vermont
  Burlington
 Fletcher Allen Health Care - Medical Center Campus
 Cheung Wong Ph: 802-656-8990
Virginia
  Charlottesville
 University of Virginia Cancer Center
 Susan C Modesitt Ph: 434-243-6143
  Richmond
 Virginia Commonwealth University Massey Cancer Center
 Weldon E Chafe Ph: 804-628-1939
  Roanoke
 Carilion Clinic Gynecological Oncology
 Janet L. Osborne Ph: 540-985-8510
Washington
  Bellingham
 PeaceHealth Medical Group, PC at St. Joseph Hospital
 Benjamin E. Greer Ph: 206-616-8289
  Bremerton
 Harrison Medical Center
 Benjamin E. Greer Ph: 206-616-8289
 Olympic Hematology and Oncology
 Benjamin E. Greer Ph: 206-616-8289
  Everett
 Providence Regional Cancer Partnership
 Benjamin E. Greer Ph: 206-616-8289
  Mount Vernon
 Skagit Valley Hospital Cancer Care Center
 Benjamin E. Greer Ph: 206-616-8289
  Poulsbo
 Harrison Poulsbo Hematology and Onocology
 Benjamin E. Greer Ph: 206-616-8289
  Seattle
 Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
 Benjamin E. Greer Ph: 206-616-8289
 Group Health Central Hospital
 Benjamin E. Greer Ph: 206-616-8289
 Pacific Gynecology Specialists
 Benjamin E. Greer Ph: 206-616-8289
 Seattle Cancer Care Alliance
 Benjamin E. Greer Ph: 206-616-8289
 Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
 Benjamin E. Greer Ph: 206-616-8289
 Swedish Cancer Institute at Northwest Hospital & Medical Center
 Benjamin E. Greer Ph: 206-616-8289
 University Cancer Center at University of Washington Medical Center
 Benjamin E. Greer Ph: 206-616-8289
  Sequim
 Olympic Medical Cancer Center
 Benjamin E. Greer Ph: 206-616-8289
  Spokane
 Cancer Care Northwest - Spokane South
 Benjamin E. Greer Ph: 206-616-8289
 Rockwood Clinic Cancer Treatment Center
 Benjamin E. Greer Ph: 206-616-8289
  Tacoma
 Franciscan Cancer Center at St. Joseph Medical Center
 Benjamin E. Greer Ph: 206-616-8289
  Vancouver
 Northwest Cancer Specialists at Vancouver Cancer Center
 Alison K Conlin Ph: 503-215-6412
 Southwest Washington Medical Center Cancer Center
 Alison K Conlin Ph: 503-215-6412
  Walla Walla
 St. Mary Regional Cancer Center at St. Mary Medical Center
 Benjamin E. Greer Ph: 206-616-8289
  Wenatchee
 Confluence Health - Wenatchee Valley Medical Center
 Benjamin E. Greer Ph: 206-616-8289
Wisconsin
  Grafton
 Aurora Cancer Care-Grafton
 Peter Johnson Ph: 800-252-2990
  Green Bay
 Green Bay Oncology, Limited at St. Mary's Hospital
 Jonathan E Tammela Ph: 920-433-8889
 Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
 Jonathan E Tammela Ph: 920-433-8889
 St. Mary's Hospital Medical Center - Green Bay
 Jonathan E Tammela Ph: 920-433-8889
 St. Vincent Hospital Regional Cancer Center
 Jonathan E Tammela Ph: 920-433-8889
 Vince Lombardi Cancer Clinic - Green Bay at Aurora BayCare Medical Center
 Peter Johnson Ph: 800-252-2990
  La Crosse
 Gundersen Lutheran Center for Cancer and Blood
 Sigurdur Bodvarsson Ph: 608-775-2385
  Email: cancerctr@gundluth.org
  Madison
 University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
 David M Kushner Ph: 877-405-6866
  Marinette
 Bay Area Cancer Care Center at Bay Area Medical Center
 Jonathan E Tammela Ph: 920-433-8889
 Vince Lombardi Cancer Clinic - Marinette
 Peter Johnson Ph: 800-252-2990
  Milwaukee
 Aurora Sinai Medical Center
 Peter Johnson Ph: 800-252-2990
 Froedtert Hospital and Medical College of Wisconsin
 William H Bradley Ph: 414-805-4380
 Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center
 Peter Johnson Ph: 800-252-2990
  Oconto Falls
 Green Bay Oncology, Limited - Oconto Falls
 Jonathan E Tammela Ph: 920-433-8889
  Oshkosh
 Vince Lombardi Cancer Clinic - Oshkosh
 Peter Johnson Ph: 800-252-2990
  Sheboygan
 Vince Lombardi Cancer Clinic - Sheboygan
 Peter Johnson Ph: 800-252-2990
  Sturgeon Bay
 Green Bay Oncology, Limited - Sturgeon Bay
 Jonathan E Tammela Ph: 920-433-8889
  Summit
 Aurora Medical Center
 Peter Johnson Ph: 800-252-2990
  Two Rivers
 Vince Lombardi Cancer Clinic - Two Rivers
 Peter Johnson Ph: 800-252-2990
  West Allis
 Aurora Women's Pavilion of West Allis Memorial Hospital
 Peter Johnson Ph: 800-252-2990
Japan
  Hiroshima City
 Hiroshima University Hospital
 Eiji Hirata Ph:  82-424-6042
  Kagoshima City, Kagoshima
 Kagoshima City Hospital
 Masayuki Hatae Ph: 011 81 099 224 2101
  Matsuyama
 Shikoku Cancer Center
 Takayoshi Nogawa Ph: 089-999-1172
  Minato-ku, Tokyo
 Jikei University School of Medicine
 Kyosuke Yamada Ph:  03-3433-1111 ext 2153
  Osaka, Osaka
 Kinki University School of Medicine
 Masaki Mandai Ph: 072-366-0221
  Saitama
 Saitama Medical University International Medical Center
 Keiichi Fujiwara Ph:  81-49-276-2028
  Tottori
 Tottori University Hospital
 Hiroaki Itamochi Ph: 0857-31-5007
Aoba-ku
  Sendai
 Tohoku University Graduate School of Medicine
 Nobuo Yaegashi
  Email: med-som@bureau.tohoku.ac.jp
Hiroshima
  Kure
 National Hospital Organization - Medical Center of Kure
 Kazuhiro Takehara Ph: 089-999-1172
Hokkaido
  Sapporo
 Hokkaido University Hospital
 Noriaki Sakuragi
  Email: hassi@med.hokudai.ac.jp
Iwate
  Morioka
 Iwate Medical University Hospital
 Toru Sugiyama Ph: 019-651-5111
Niigata
  Niigata City
 Niigata University Medical and Dental Hospital
 Takayuki Enomoto Ph: 81-025-223-6161
Suntou
  Shizuoka City
 Shizuoka Cancer Center
 Munetaka Takekuma Ph: 888-823-5923
  Email: ctsucontact@westat.com
Tokyo
  Shinjuku-ku
 Keio University Hospital
 Daisuke Aoki Ph:  03 5363-3848
Republic of Korea
  Seoul
 Asan Medical Center - University of Ulsan College of Medicine
 Joo-Hyun Nam Ph: 011-82-760-2384
 Gangnam Severance Hospital
 Jae-Hoon Kim
  Email: clinical.trial@bms.com
 Korea Cancer Center Hospital
 Moon-Hong Kim Ph: 011-82-02-9702-114
 Seoul National University Hospital
 Jae W Kim Ph: 011-82-760-2384
Daegu
  Jung-Ku
 Dongsan Medical Center of Keimyung University
 Chi-Heum Cho
  Email: ho@dsmc.or.kr
Gyeonggi-do
  Goyang-si
 National Cancer Center - Korea
 Sang Y Park Ph: 011-82-760-2384
KOREA
  Seoul
 Catholic University of Korea College of Medicine
 Jong-Sup Park Ph:  2258-5745-6
 Samsung Medical Center
 Duk-Soo Bae Ph: 011-82-1599-3114

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00565851
ClinicalTrials.gov processed this data on February 11, 2014

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top